Verastem
VSTM
Market cap $115M

2.87 USD

+0.10

3.61%

At close Oct 4, 4:00 PM EDT

After hours

2.93

+0.06

2.09%

1 day

3.61%

5 days

2.50%

1 month

17.62%

3 months

4.74%

6 months

-74.67%

Year to date

-65.42%

1 year

-61.22%

5 years

-79.90%

About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Employees: 73

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

141% more call options, than puts

Call options by funds: $181K | Put options by funds: $75K

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

4% less funds holding

Funds holding: 70 [Q1] → 67 (-3) [Q2]

7.77% less ownership

Funds ownership: 66.89% [Q1] → 59.12% (-7.77%) [Q2]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

78% less capital invested

Capital invested by funds: $200M [Q1] → $44.7M (-$155M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

144%

upside

Avg. target

$12.17

324%

upside

High target

$18

527%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Michael Schmidt 29% 1-year accuracy 2 / 7 met price target	353%upside $13	Buy Initiated	30 Sept 2024
Truist Securities Srikripa Devarakonda 58% 1-year accuracy 11 / 19 met price target	423%upside $15	Buy Maintained	13 Aug 2024
HC Wainwright & Co. Sean Lee 50% 1-year accuracy 2 / 4 met price target	144%upside $7	Buy Maintained	12 Aug 2024
RBC Capital Gregory Renza 41% 1-year accuracy 12 / 29 met price target	353%upside $13	Outperform Maintained	9 Aug 2024
B. Riley Securities Kalpit Patel 0 / 0 met price target	144%upside $7	Buy Maintained	24 Jul 2024

See Analyst Rankings

Financial journalist opinion

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A replay of.

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor regression in 86%.

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

BOSTON & HOUSTON, Texas--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024. September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian cancer with little information and awareness available to patients and caregivers. This newly created.

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the second quarter ended June 30, 2024. “We have made tremendous progress in the second quarter as we initiated our rolling NDA submission for avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer, shared updated topline results from our.

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, in combination with defactinib, a selective FAK inhibitor, for the treatment of pancreatic cancer. “At the ASCO 2024 Annual Meeting, we reported positive initial interim results from the ongoing RAMP 205 trial evaluating.

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

BOSTON---(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of its common stock at a combined offering price to the public of $3.00 per share and accompanying warrant. In lieu of common stock to certain investors, Verastem Oncology offered p.

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants to purchase common stock in lieu of common stock for certain investors and accompanying warrants to purchase shares of common stock, in an underwritten public offering. The pre-f.

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Zacks Investment Research

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ:VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

See News Rankings

Charts implemented using Lightweight Charts™